Pipeline

ABL111

HomePipelineABL111

  • Pipeline
    ABL111
  • Program Target
    Claudin18.2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL111 is a bispecific antibody combining Claudin18.2, a gastric- and pancreatic-specific cancer antigen with 4-1BB agonistic activity to supercharge T cells in a Claudin18.2-dependent manner, enhancing anti-tumor immunity while minimizing 4-1BB related toxicity. ABL111 is full length anti-Claudin18.2 mAb (Fc-silenced human IgG1) fused with scFv of anti-4-1BB engaging mAb. ABL111 possesses unique properties that 4-1BB activation signal is dependent on Claudin18.2 expression. ABL111 shows superior anti-tumor activity in an animal model system than Claudin18.2 alone, 4-1BB alone or combination of both with immunological memory resistant to rechallenge with same tumors.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

Claudin18.2 Dependent 4-1BB Activation

Claudin18.2 Dependent 4-1BB Activation
Claudin18.2 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
좌우스크롤 Superior Anti-Tumor Effect with Immunological Memory